UroAlerts - Prostate Cancer Weekly

November 19, 2024

Videos

Peer-to-Peer Clinical Conversations

ctDNA Assay Detects AR Enhancer Alterations Linked to Poor Survival - Russell Pachynski, Aadel Chaudhuri & Christopher Maher

Chris Maher

Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer.

APCCC 2024 Highlights Patient Voice in Cancer Treatment "Presentation" - Silke Gillessen, Aurelius Omlin & David Matheson

Silke Gillessen

At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Silke Gillessen and Aurelius Omlin introduce the international panel of experts and voting process, followed by patient advocate David Matheson's presentation on the importance of understanding patients' dual experience of illness and wellness, emphasizing the critical role of hope in treatment and the need for more patient-centered quality of life tools.

Beyond the Abstracts

First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma - Beyond the Abstract

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer.

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.

Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance.

[225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer.

Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation.

Striving for Equity: Examining Health Disparities in Urologic Oncology.

Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.

St Vincent’s Hospital to Conduct Head-to-Head Trial with Clarity’s SAR-bisPSMA Diagnostic Product

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.

Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries.

HSD3B1, prostate cancer mortality and modifiable outcomes.

Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.

A Novel Machine Learning-Based Predictive Model of Clinically Significant Prostate Cancer and Online Risk Calculator.

The Role of Nuclear Medicine in Imaging and Therapy of Prostate Cancer: The State of the Art.

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.

Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.

Preclinical and Clinical Evidence for Using Perinatal Tissue Allografts in Nerve Sparing Robot Assisted Radical Prostatectomy to Hasten Recovery of Functional Outcomes: A Literature Review - Beyond the Abstract

Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohort.

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.

Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer.

Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.

Study on the Impact of Hormone Therapy for Prostate Cancer on the Quality of Life and the Psycho-Relational Sphere of Patients: ProQoL.

Imaging in Diagnosis and Active Surveillance for Prostate Cancer: A Review.

A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol.

PRO-P: evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled trial.

Update on PSMA-based Prostate Cancer Imaging.

Use of Placebo in Urologic Oncology Randomized Controlled Trials.

Optimizing radiomics for prostate cancer diagnosis: feature selection strategies, machine learning classifiers, and MRI sequences.

Evaluating the Role of Ultrasound in Prostate Cancer trial - phase 1: Early experience of micro-ultrasound in the United Kingdom.

Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy.

Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.

Repeatability of quantitative MR fingerprinting for T1 and T2 measurements of metastatic bone in prostate cancer patients.

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data - Beyond the Abstract

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC